The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

For the third time in four years, CNBC ranks North Carolina as Top State for Business. To learn more, click here. Hosted by the Central Carolina Community College's (CCCC) Biotechnology Department, ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Instead of making one-off treatments, industrialized gene therapy might be able to treat multiple diseases.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may play an important role in colon cancer. Researchers also showed how ...

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient ...

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized approach to precision medicine, as published in Frontiers in Science ...